APO 010

Drug Profile

APO 010

Alternative Names: APO-010

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apoxis
  • Developer Oncology Venture A/S; Onxeo SA
  • Class Antineoplastics; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for phase-I development in Solid-tumours in Switzerland (IV, Injection)
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in Switzerland (IV, Injection)
  • 24 Aug 2018 Medical Prognosis Institute merged with Oncology Venture and the former changed its name to Oncology Venture A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top